
INTRODUCTION


- The Enhanced Delivery Oligonucleotide (EDO) platform is engineered to optimize the tissue penetration, cellular uptake and nuclear delivery of oligonucleotide therapeutic candidates.
- DM1 is a multi-systemic disease that has a **significant impact** on the quality of life.
- Limited delivery and distribution of unconjugated oligonucleotides to affected tissues limits their activity in DM1.
- **PGN-EDODM1** is an EDO under investigation for the treatment of people with DM1.
- PGN-EDODM1 was evaluated in multiple nonclinical models including DM1 cells, the HSA^{LR} mouse model of DM1 and in wild-type (WT) mice and non-human primates (NHPs).

PGN-EDODM1 IS DESIGNED TO LIBERATE MBNL1 WITHOUT REDUCING DMPK LEVELS

DM1 PATHOLOGY

DMPK transcript CUG repeat hairpin loops bind MBNL1 and form foci






Expanding foci trap more MBNL1

MBNL1 COMPETITION

PGN-EDODM1 binds CUG repeats in DMPK transcript, reducing foci



- Binding of PGN-EDODM1 liberates MBNL1, restoring physiological splicing
- DMPK transcript retained; role in cellular processes uninterrupted

denotes free (active) MBNL1,




PGN-EDODM1 Nonclinical Data Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of Myotonic Dystrophy Type 1 (DM1)


Ashling Holland¹, Arnaud Klein², Pallavi Lonkar¹, Niels Svenstrup¹, Brijesh Garg¹, Denis Furling², Jaya Goyal¹

¹PepGen Inc. Boston, MA, USA, ²Institut de Myologie, Paris, France


PGN-EDODM1 REDUCED FOCI, LIBERATED MBNL1 and CORRECTED MIS-SPLICING IN DM1 CELLS



A SINGLE DOSE OF PGN-EDODM1 ACHIEVED CORRECTION OF MIS-SPLICING AND MYOTONIA IN HSALR MODEL





REPEAT DOSING OF PGN-EDODM1 IN HSALR MICE ENHANCED CORRECTION OF MIS-SPLICING, REVERSED MYOTONIA AND INCREASED MUSCLE DELIVERY




*Investigational New Drug (IND) for FREEDOM-DM1 study of PGN-EDODM1 in patients with DM1 is currently on clinical hold with FDA. PepGen is working to address FDA's feedback.

MIS-SPLICING CORRECTION





FREEDOM-DM1 PHASE 1 CLINICAL STUDY



- Canada
- study*.

PGN-EDODM1 DID NOT TARGET DMPK FOR DEGRADATION

DMPK TRANSCRIPT LEVELS

• Observed to be well-tolerated through 90 mg/kg in single dose NHP GLP toxicology studies

• FREEDOM-DM1 Phase 1 randomized, double-blind, placebo-controlled SAD study in patients is open in

• Nonclinical data in DM1 cells, HSA^{LR} mice and non-human primates support the continued clinical development of PGN-EDODM1 and planned FREEDOM-DM1 Phase 1 clinical

